The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

US Government Contract Win

28 Feb 2013 07:00

RNS Number : 8492Y
Instem plc
28 February 2013
 

28 February 2013

 

Instem plc

("Instem", or, the "Company")

 

US Government Contract Win

 

Provantis Preclinical Software Chosen for National Toxicology Program by National Institute of Environmental Health Sciences

 

Instem (AIM:INS), a leading provider of IT solutions to the global early development healthcare market, announced today that the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health (NIH), has purchased the Provantis 9® preclinical software suite via SaaS (Software-as-a-Service) to support National Toxicology Program studies. These Reproductive, Immunotox, Neurobehavioural, Sensitisation and Carcinogenicity studies are primarily carried out at contractor laboratory sites throughout the United States.

 

The value of the award to Instem, funded completely by the US government, is approximately $870,000 in the first year, with potential to extend and expand the agreement up to a further 9 years, giving a possible total contract value for all 10 years of between $6.2m-$7.6m. The contract also includes the ability to expand to a larger number of additional sites on the same terms, which could result in further material increase in revenue.

 

The National Toxicology Program (NTP) is an interagency program established in 1978 to coordinate toxicology research and development across the Department of Health and Human Services. The program was also created to strengthen the science base in toxicology, develop and validate improved testing methods and provide information about potentially toxic chemicals to health regulatory and research agencies, scientific and medical communities, and the public.

 

Headquartered at NIEHS, the NTP is managed by the NIEHS and supported by the United States Food and Drug Administration and the Centers for Disease Control and Prevention.

 

Phil Reason, CEO of Instem plc, commented, "Such a significant contract with the US government, won through a competitive tendering process, is not only a fantastic endorsement of Instem's innovative software but also of our strategy to support collaborative working practices. Our SaaS delivery model enables the sharing of the software between dispersed communities from multiple organisations, The accessibility of Provantis data will also enable the National Institute of Environmental Health Sciences to meet a key goal of combining study information with a broader set of biology information to improve scientific insights.

 

"This long term contract will also provide funding for the development of the Provantis suite in areas specific to the National Toxicology Program, adding further depth to our market leading study management platform and positioning Instem well for anticipated contract extensions and any similar future projects."

 

 

For further information, please contact:

 

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

Nigel Goldsmith, CFO

 

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Aubrey Powell

Joe Stroud

 

Newgate Threadneedle

+44 (0) 20 7653 9850

Caroline Evans-Jones

Fiona Conroy

 

 

 

 

About Instem plc

 

Instem is a leading supplier of IT solutions to the early development healthcare market. Instem's pre-clinical study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.

 

Instem has over 130 customers in North America, Europe, Australia, China, India, Singapore and Japan, including 16 of the top 20 pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Group employs over 110 people in seven offices in the US, UK, China and India; and has a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software, making Instem an ideal partner to help unlock the scientific/commercial value from these legacy repositories.

 

To learn more about Instem please visit the Company's website, www.instem.com, or its investor centre http://investors.instem.com/

 

About NIEHS

The NIEHS supports research to understand the effects of the environment on human health and is part of the National Institutes of Health (NIH). Its mission is to reduce the burden of human illness and disability by understanding how the environment influences the development and progression of human disease.

 

For more information on environmental health topics, visit www.niehs.nih.gov.

 

The NIH - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

 

This project has been funded in whole or in part with Federal funds from the National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN27320130004C.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTDXGDDSBDBGXR
Date   Source Headline
29th May 20137:00 amRNSGlobal R&D Organisation selects Centrus & SRS
23rd May 20133:08 pmRNSResult of AGM
13th May 20137:00 amRNSAcquisition of Logos Technologies
26th Apr 20134:48 pmRNSPosting of Annual Report, Notice of AGM
23rd Apr 20136:20 pmRNSHolding(s) in Company
18th Apr 20137:00 amRNSCustomer Wins for New Provantis Release
27th Mar 20137:00 amRNSFinal Results
12th Mar 20137:00 amRNSNotice of Final Results
1st Mar 20133:25 pmRNSHolding(s) in Company
28th Feb 20137:00 amRNSUS Government Contract Win
30th Jan 20139:42 amRNSHolding(s) in Company
21st Jan 20137:00 amRNSHolding(s) in Company
10th Jan 20137:01 amRNSJOINN Laboratories China Purchases Provantis
10th Jan 20137:00 amRNSTrading Update
24th Dec 20127:00 amRNSTrading Update
18th Dec 20127:00 amRNSMulti-year Contract Extension & New Awards
3rd Dec 20127:00 amRNSCentrus Contract Win
7th Nov 20127:00 amRNSContract Win with US Government Research Agency
29th Oct 20127:00 amRNSChange of name of Nominated Adviser and Broker
19th Sep 20127:00 amRNSUnaudited Interim Results
5th Sep 20127:00 amRNSNotice of Interim Results
26th Jul 20127:00 amRNSTrading Update
25th Jul 20125:40 pmRNSHolding(s) in Company
22nd May 20123:46 pmRNSResult of AGM
8th May 201212:11 pmRNSPosting of Annual Report, Notice of AGM
24th Apr 20129:17 amRNSHolding(s) in Company
30th Mar 20124:52 pmRNSTotal Voting Rights and Capital
29th Mar 20122:49 pmRNSHolding(s) in Company
28th Mar 20127:00 amRNSFinal Results
26th Mar 20127:00 amRNSEstablishment of Instem India
8th Mar 20127:00 amRNSIssue of Equity and Director/PDMR Shareholding
20th Feb 20127:00 amRNSNotice of Final Results
9th Feb 20128:34 amRNSDirector/PDMR Shareholding
1st Feb 20129:14 amRNSAppointment of Nominated Adviser and Broker
18th Jan 20126:21 pmRNSChange of Name
9th Jan 20127:00 amRNSTrading Update
30th Nov 20113:57 pmRNSAppointment of CFO
21st Sep 20117:00 amRNSUnaudited Interim Results
10th Aug 20112:57 pmRNSNotification of Death of Director
4th May 20115:32 pmRNSPosting of Annual Report & Notice of AGM
22nd Mar 20117:00 amRNSFinal Results
4th Mar 20117:00 amRNSAcquisition of BioWisdom
19th Jan 20117:00 amRNSTrading Update
29th Oct 201011:34 amRNSTotal Voting Rights
19th Oct 20107:00 amRNSHolding(s) in Company
15th Oct 201010:38 amRNSHolding(s) in Company
13th Oct 20107:00 amRNSFirst Day of Dealings on AIM
19th Feb 20083:38 pmRNSDividend Declaration
15th Feb 200811:34 amRNSResults of GM
31st Jan 20083:28 pmRNSNotification of Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.